Greta Busch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Greta Busch has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Anne Bernadette Chang
Charles Darwin University Darwin Northern Territory Australia
3 shared publications Aleta G. Knowles
Elanco Animal Health, West Ryde, NSW 2114, Australia
1 shared publication- Alicja Lew-Tabor
The University of Queensland
1 shared publication - Catherine Ann Byrnes
Starship Children's Health and Department of Paediatrics, University of Auckland, Auckland, New Zealand
1 shared publication Chian Teng Ong
Queensland Alliance for Agriculture & Food Innovation, The University of Queensland, St. Lucia, Queensland 4072, Australia
1 shared publicationDanielle F. Wurzel
Infection and Immunity, Murdoch Children's Research Institute; Respiratory and Sleep Medicine The Royal Children's Hospital Melbourne VIC Australia
1 shared publication
Latest Publications
- 12 October 2020
- Published by Wiley in Respirology
- Vol. 26 (3) , 241-248
Outcomes of protracted bacterial bronchitis in children: A 5‐year prospective cohort study
Background and objective: Long‐term data on children with PBB has been identified as a research priority. We describe the 5‐year outcomes for children with PBB to ascertain the presence of chronic respiratory disease (bronchiectasis, recurrent PBB and asthma) and identify the risk factors for these.Methods: Prospective cohort study was undertaken at the Queensland Children's Hospital, Brisbane, Australia, of 166 children with PBB and 28 controls (undergoing bronchoscopy for symptoms other than chronic wet cough). Monitoring was by monthly contact via research staff. Clinical review, spirometry and CT chest were performed as clinically indicated.Results: A total of 194 children were included in the analysis. Median duration of follow‐up was 59 months (IQR: 50–71 months) post‐index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow‐up (ORadj = 9.6, 95% CI: 1.8–50.1) and the presence of Haemophilus influenzae in the BAL (ORadj = 5.1, 95% CI: 1.4–19.1). Clinician‐diagnosed asthma at final follow‐up was present in 27.1% of children with PBB. A significant BDR (FEV1 improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen‐specific IgE (ORadj = 14.8, 95% CI: 2.2–100.8) at baseline and bronchomalacia (ORadj = 5.9, 95% CI: 1.2–29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range.Conclusion: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.
- 12 October 2020
- Published by Wiley in Respirology
- Vol. 26 (3) , 241-248
Outcomes of protracted bacterial bronchitis in children: A 5‐year prospective cohort study
Background and objective: Long‐term data on children with PBB has been identified as a research priority. We describe the 5‐year outcomes for children with PBB to ascertain the presence of chronic respiratory disease (bronchiectasis, recurrent PBB and asthma) and identify the risk factors for these.Methods: Prospective cohort study was undertaken at the Queensland Children's Hospital, Brisbane, Australia, of 166 children with PBB and 28 controls (undergoing bronchoscopy for symptoms other than chronic wet cough). Monitoring was by monthly contact via research staff. Clinical review, spirometry and CT chest were performed as clinically indicated.Results: A total of 194 children were included in the analysis. Median duration of follow‐up was 59 months (IQR: 50–71 months) post‐index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow‐up (ORadj = 9.6, 95% CI: 1.8–50.1) and the presence of Haemophilus influenzae in the BAL (ORadj = 5.1, 95% CI: 1.4–19.1). Clinician‐diagnosed asthma at final follow‐up was present in 27.1% of children with PBB. A significant BDR (FEV1 improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen‐specific IgE (ORadj = 14.8, 95% CI: 2.2–100.8) at baseline and bronchomalacia (ORadj = 5.9, 95% CI: 1.2–29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range.Conclusion: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.
- Open Access
- 13 August 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-9
Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study
Bronchiectasis in children is an important, but under-researched, chronic pulmonary disorder that has negative impacts on health-related quality of life. Despite this, it does not receive the same attention as other chronic pulmonary conditions in children such as cystic fibrosis. We measured health resource use and health-related quality of life over a 12-month period in children with bronchiectasis. We undertook a prospective cohort study of 85 children aged < 18-years with high-resolution chest computed-tomography confirmed bronchiectasis undergoing management in three pediatric respiratory medical clinics in Darwin and Brisbane, Australia and Auckland, New Zealand. Children with cystic fibrosis or receiving cancer treatment were excluded. Data collected included the frequency of healthcare attendances (general practice, specialists, hospital and/or emergency departments, and other), medication use, work and school/childcare absences for parents/carers and children respectively, and both parent/carer and child reported quality of life and cough severity. Overall, 951 child-months of observation were completed for 85 children (median age 8.7-years, interquartile range 5.4–11.3). The mean (standard deviation) number of exacerbations was 3.3 (2.2) per child-year. Thirty of 264 (11.4%) exacerbation episodes required hospitalization. Healthcare attendance and antibiotic use rates were high (30 and 50 per 100 child-months of observation respectively). A carer took leave from work for 53/236 (22.5%) routine clinic visits. Absences from school/childcare due to bronchiectasis were 24.9 children per 100 child-months. Quality of life scores for both the parent/carer and child were highly-correlated with one another, remained stable over time and were negatively associated with cough severity. Health resource use in this cohort of children is high, reflecting their severe disease burden. Studies are now needed to quantify the direct and societal costs of disease and to evaluate interventions that may reduce disease burden, particularly hospitalizations.
- 13 August 2019
- Published by Springer Nature in BMC Health Services Research
- Vol. 19 (1) , 1-9
Open AccessHealth-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study
Bronchiectasis in children is an important, but under-researched, chronic pulmonary disorder that has negative impacts on health-related quality of life. Despite this, it does not receive the same attention as other chronic pulmonary conditions in children such as cystic fibrosis. We measured health resource use and health-related quality of life over a 12-month period in children with bronchiectasis. We undertook a prospective cohort study of 85 children aged < 18-years with high-resolution chest computed-tomography confirmed bronchiectasis undergoing management in three pediatric respiratory medical clinics in Darwin and Brisbane, Australia and Auckland, New Zealand. Children with cystic fibrosis or receiving cancer treatment were excluded. Data collected included the frequency of healthcare attendances (general practice, specialists, hospital and/or emergency departments, and other), medication use, work and school/childcare absences for parents/carers and children respectively, and both parent/carer and child reported quality of life and cough severity. Overall, 951 child-months of observation were completed for 85 children (median age 8.7-years, interquartile range 5.4–11.3). The mean (standard deviation) number of exacerbations was 3.3 (2.2) per child-year. Thirty of 264 (11.4%) exacerbation episodes required hospitalization. Healthcare attendance and antibiotic use rates were high (30 and 50 per 100 child-months of observation respectively). A carer took leave from work for 53/236 (22.5%) routine clinic visits. Absences from school/childcare due to bronchiectasis were 24.9 children per 100 child-months. Quality of life scores for both the parent/carer and child were highly-correlated with one another, remained stable over time and were negatively associated with cough severity. Health resource use in this cohort of children is high, reflecting their severe disease burden. Studies are now needed to quantify the direct and societal costs of disease and to evaluate interventions that may reduce disease burden, particularly hospitalizations.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , OA3608
Outcomes in protracted bacterial bronchitis (PBB): a five year prospective cohort study
Introduction: Protracted bacterial bronchitis (PBB), the commonest cause of chronic cough in childhood, is characterised by chronic wet cough (>4 weeks duration) that usually responds to 2-wks of appropriate antibiotic therapy without evidence of an alternative cause for cough. There are no long term studies on PBB beyond 2 yrs. Objectives: Characterise the 5 yr outcomes for children with PBB. Methods: 151 children (median age 26-mo, range 4-163) requiring bronchoscopy (FB) were recruited (PBB=130, controls=21). Participants were followed up for 5 yrs (min 42 mo). Participants were monitored with monthly contact via research staff and when possible annual clinical review and spirometry. CT chest was performed if symptoms/signs suggestive of bronchiectasis were present. Asthma was defined as a doctor diagnosis. Results: Of the 130 children with PBB, 88 (68%) had trachea/bronchomalacia on FB. CT chest was performed on 59 children (max 28 mo post FB), 11 (8.5%) had bronchiectasis. The incidence of recurrent PBB (>3 episodes/yr) decreased over study time from 70 (53.8%) in Yr-1 to 8 (15.7%) in Yr-5. However 38 (60.3%) required at least one course of antibiotics for an episode of wet cough in the preceding year. At the Yr-5 evaluation, 34 children with PBB (45.9%) had a diagnosis of asthma vs 2 (14%) in the controls (p<0.001) but with similar spirometry (FEV1 93.1%pred ± SD 15 and 93.0% ± 11.5 respectively). Conclusion: Children with PBB should be followed-up as a significant proportion will eventually develop bronchiectasis and/or an asthma phenotype. Identifying clinical and/or lab-based markers (e.g. molecular signatures) at the index PBB episode would be useful for predicting future risk of disease.
- 15 September 2018
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 52 (suppl 62) , OA3608
Outcomes in protracted bacterial bronchitis (PBB): a five year prospective cohort study
Introduction: Protracted bacterial bronchitis (PBB), the commonest cause of chronic cough in childhood, is characterised by chronic wet cough (>4 weeks duration) that usually responds to 2-wks of appropriate antibiotic therapy without evidence of an alternative cause for cough. There are no long term studies on PBB beyond 2 yrs. Objectives: Characterise the 5 yr outcomes for children with PBB. Methods: 151 children (median age 26-mo, range 4-163) requiring bronchoscopy (FB) were recruited (PBB=130, controls=21). Participants were followed up for 5 yrs (min 42 mo). Participants were monitored with monthly contact via research staff and when possible annual clinical review and spirometry. CT chest was performed if symptoms/signs suggestive of bronchiectasis were present. Asthma was defined as a doctor diagnosis. Results: Of the 130 children with PBB, 88 (68%) had trachea/bronchomalacia on FB. CT chest was performed on 59 children (max 28 mo post FB), 11 (8.5%) had bronchiectasis. The incidence of recurrent PBB (>3 episodes/yr) decreased over study time from 70 (53.8%) in Yr-1 to 8 (15.7%) in Yr-5. However 38 (60.3%) required at least one course of antibiotics for an episode of wet cough in the preceding year. At the Yr-5 evaluation, 34 children with PBB (45.9%) had a diagnosis of asthma vs 2 (14%) in the controls (p<0.001) but with similar spirometry (FEV1 93.1%pred ± SD 15 and 93.0% ± 11.5 respectively). Conclusion: Children with PBB should be followed-up as a significant proportion will eventually develop bronchiectasis and/or an asthma phenotype. Identifying clinical and/or lab-based markers (e.g. molecular signatures) at the index PBB episode would be useful for predicting future risk of disease.
- 1 January 2018
- Published by Elsevier in International Journal for Parasitology
- Vol. 48 (1) , 71-82
Transcriptome and toxin family analysis of the paralysis tick, Ixodes holocyclus
- 1 January 2018
- Published by Elsevier in International Journal for Parasitology
- Vol. 48 (1) , 71-82
Transcriptome and toxin family analysis of the paralysis tick, Ixodes holocyclus